trending Market Intelligence /marketintelligence/en/news-insights/trending/tGEHDlJv4woX1ABwnG1exQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Eli Lilly migraine drug meets primary endpoint in phase 3 trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Eli Lilly migraine drug meets primary endpoint in phase 3 trial

Eli Lilly and Co. said its migraine drug lasmiditan met the primary and secondary endpoints in a second phase 3 study.

A greater percentage of patients treated under the study were migraine pain-free when compared to placebo and experienced no bothersome symptoms such as nausea and sensitivity to sound or light.

The most commonly reported adverse events after the drug's dosing were dizziness, paresthesia, somnolence, fatigue, nausea and lethargy.

Eli Lilly plans to submit a new drug application for lasmiditan with the U.S. Food and Drug Administration in the second half of 2018, the company said in a news release.

Findings from the study are consistent with the results from an earlier phase 3 trial.

Meanwhile, lasmiditan could potentially be paired with Lilly's chronic and episodic migraine drug galcanezumab, which met its primary endpoints in three phase 3 studies in May.